# Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

> **NCT00190736** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 440 (—)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** Atomoxetine Hydrochloride
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00190736
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 440 (—)
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00190736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00190736, "Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00190736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*